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significantly upregulated on day 2 after 4 Gy in-vitro irradiation in 
both groups (approximately 6-fold in controls and 2.5-fold in cases), 
but appears to decay more slowly in fibroblasts from cases. However, 
cases show a significantly higher level of p53 than controls (p=0.0205) 
and this effect independent of any further radiation exposure.  
Conclusions: DNA damage, in particular unrepaired DSB is not a 
significant factor in the development of late breast fibrosis after 
radiotherapy. 
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Purpose/Objective: To validate the hypothesis that: a) The increase 
of esophagus SUVmax one week after the start of radiotherapy 
treatment is correlated with parallel severe dysphagia level (grade ≥ 
2); b) The increase of esophagus SUVmax at one specific level is 
correlated to the dose given at this specific level and c) To investigate 
whether some specific anatomical regions of the esophagus (divided 
into 3 equal parts) are more sensitive to inflammation than others. 
Materials and Methods: A cohort of 39 non-small cell lung cancer 
patients treated with curative intend and having had two FDG PET 
scans: one before treatment and approximately one week after start 
of treatment (average 9 ± 2 days). Dysphagia toxicity, PET and CT 
scans were analyzed for each patient. The esophagus has been divided 
into 3 equal regions: a caudal region (part 1), a middle region (part 2) 
and a cranial region (part 3). 
-The maximal PET-SUV value in the esophagus (SUVmax) was 
computed, excluding the GTV regions, for the whole esophagus and 
for each part of the esophagus on both time points. The change in 
SUVmax, ΔSUVmax, was calculated. This change was correlated to the 
incidence of severe dysphagia (grade ≥2).  
-The patients were divided into 2 groups: one group (Gr 2) consisted 
of patients with dysphagia toxicity larger than grade 2 and the other 
group (Gr 1) contained patients with mild or no dysphagia (grade 0 or 
1). The average difference of SUVmax is measured for each of the 
groups, ΔSUVmax. 
-The dose was computed for each esophageal region. We then 
correlated the dose given to each third to the ΔSUVmax on the 
corresponding region. 
Results: The dose delivered to the patients until the second PET/CT 
scan was on average 21 ± 3 Gy.  
-The increase in SUVmax was significantly higher in the severe 
dysphagia group (ΔSUVmax = 0.34 ± 0.66 of increase in Gr 2) than for 
patients without dysphagia toxicity (-0.17 ± 2.1). By using the one-
sided Wilcoxon rank sum test, the p-value was significant (p=0.055).  
-The increase of SUVmax was highest in the most caudal part of the 
esophagus for the patients having severe dysphagia: ΔSUVmax = 0.53 
±0.81 compared to the patients without toxicity: ΔSUVmax = 0.18 ± 
1.3, with a trend towards significance (p-value =0.06).  
-The increase in SUVmax for the middle and cranial parts were not 
significant (large p-values > 0.20).  
Conclusions: Significant increase in SUVmax for patients with severe 
dysphagia was observed. The increase in the caudal third of the 
esophagus was higher for patients with severe dysphagia compared to 
the other parts of the esophagus. A validation study or an extension of 
the cohort patients is however necessary. 
Figure 1. Summary showing for each part of the esophagus the 
difference of ΔSUV(MAX) for each region of the esophagus: its value 
(of increase), standard deviation, p-value and significance of the one-
sided Wilcoxon rank sum test. 
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Purpose/Objective: Novel radiotherapy techniques such as 
stereotactic radiosurgery (SRS), stereotactic body radiation therapy 
(SBRT), high-dose-rate (HDR), brachytherapy boost, and intra-
operative radiotherapy (IORT), use a single or very few, very large 
dose fractions. Furthermore, the total time required to apply a dose 
fraction may be increased, allowing induction and repair of sublethal 
lesions during the treatment. In addition, IORT potentially influences 
subsequent wound healing. This departure from conventional 
fractionated radiotherapy may influence the biological effect in 
several ways. The purpose was to study the influence of high single 
doses, and protracted irradiation, on RBE, repair, and wound healing 
in vitro. 
Materials and Methods: Human MCF7 breast cancer cells, normal skin 
fibroblasts and endothelial cells (HUVEC), and hamster V79 cells, were 
used. Irradiation was performed with 50 kV X-rays from the 
Intrabeam® machine with a 4 cm applicator for tumour-bed 
irradiation (Carl Zeiss Surgical, Oberkochen, Germany) or 6 MV X-rays 
from a linear accelerator. Clonogenic cell survival was determined by 
the colony formation assay; repair halftimes of sublethal damage 
(SLD) were determined from split-dose experiments; DNA double-
strand breaks (DSB) were monitored by phosphorylated histone γH2AX 
foci; cell migration was quantified by the in vitro wound healing 
(scratch) assay. 
Results: The RBE of 50 kV X-rays was increased relative to 6 MV (mean 
1.35; 95% c.i.;1.2-1.5) at 8.1 mm depth in a water-equivalent tumour-
bed phantom (dose rate 15.1 Gy/min) but a decrease with increasing 
dose as predicted by the linear-quadratic (L-Q) formalism was not 
observed. However, RBE was decreased irrespective of dose at the 
lower dose rate of 9.8 Gy/min in 12.7 mm depth. This could be partly 
explained by continuous induction and repair of SLD during protracted 
irradiation. On the other hand, residual γH2AX foci in V79 cells 24h 
after irradiation with 4.7 Gy (equivalent to approximately 6 Gy of 6 
MV X-rays) decreased with decreasing dose rate (25 to 7 Gy/h) in air, 
indicating a possible limiting role of the DSB repair system. Whereas a 
dose of 12 Gy of 6 MV X-rays strongly inactivated fibroblast colony 
formation, migration in the wound healing assay was not inhibited, 
and even slightly stimulated, by irradiation. The cytokine TGF-β1, 
which plays a central role in wound healing, inhibited migration but 
no interaction between irradiation and TGF-β1 was observed. 
Conclusions: The RBE, and effects of repair during protracted dose 
delivery, should be taken into account when assessing biological 
effects of large dose fractions of IORT. However, deviations from the 
dose dependence predicted by the L-Q formalism were observed. 
Unexpectedly, no adverse effect of high-dose irradiation on migration 
was observed in the absence or presence of TGF-β1. Further studies of 
the biological effects of very large dose fractions are warranted. 
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Purpose/Objective: The effects of radio-adaptive response is the 
main interest many studies.The exposure of cell lines to low-dose 
irradiation leads to changes at molecular level which may induce 
adaptive response. Cells and tissues exposure to low doses followed by 
higher irradiation doses is named radioadaptive irradiation. Adaptive 
response can lead to hypersensitivity or radioresistance. The aim of 
this research was to examine the effects of everyday low-dose pre-
irradiation on cell viability in two cell lines: cancer cells and fetal 
lung fibroblasts. 
Materials and Methods: We studied the effect of a low-dose pre-
irradiation (0.03Gy, 0.05Gy and 0.07 Gy), applicated everyday solely 
and also everyday prior to 2.0Gy challenging dose after two hours, on 
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the survival of the HT29 cell line (human colorectal cancer cells) and 
on the MRC5 cell line(human fetal lung fibroblasts). Overall irradiation 
time was for four days,once per day. Cell viability was tested by dye 
exclusion test (DET) using trypan blue dye, 24 hours after last 
irradiation session and the total cell number was estimated. Both cell 
lines were irradiated using phantom constructed specially for this 
experiment. Obtained data were processed in STATISTICA ver. 10 
software and basic statistical calculations were performed. 
Results: The low-doses of 0.03Gy and 0.05Gy given alone every day 
during four day period did not have any significant effect on both cell 
lines, while 0.07Gy significantly reduced the cell survival. Same doses 
applied every day two hours before the 2.0Gy fraction, in four days 
overall treatment time, gave different response. The low-dose of 0.05 
Gy led to a significantly induced radiosensitivity in HT29 cells, but not 
in MRC5 cells, while 0.07Gy encreased even more the radiosensitivity 
in human colorectal cancer cells. Contrary, same pre-irradiation dose 
led to a significant radioresistancy in MRC5 cells. 
Conclusions: The pre-irradiation doses of 0.05 and 0.07Gy prior to the 
2Gy fraction increase cell killing in human colorectal cancer cells, and 
at the same time have no significant effect on the survival of human 
fetal lung fibroblasts. Even though these results represent promising 
effect of applied low-dose pre-irradiation with 2Gy fraction 
afterwards, these findings should be proved in vivo, and finally 
implemented as method of choice in radiotherapy treatment. 
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Purpose/Objective: Main radiotherapy problem of cancer treatment is 
side-effect as a result of high dose of radiation. All of the modern 
apparatus for cancer therapy are not enough efficient when low-doses 
applying. It related with the biological sensitivity and reaction of 
tumor cells on radiation. Biological effects could be increased by using 
pulse-modulated radiation. It could allowed to significantly decrease 
radiation dose with saving antitumor efficacy. The source of low-dose 
repetitively pulsed X-ray radiation was first developed and created at 
the Institute of high-current electronics (Russia). 
Materials and Methods: 'Sinus-150' as a generator of pulse periodic X-
ray was applied. A high-voltage pulse had a half-height duration of 4 
ns and amplitude of 260 kV. The calculated photon energy spectrum 
had a maximum at 90 keV, and most of the quantum flux was the 60-
200 keV range. Dose per pulse was 0.3 mR, absorbed dose were 0.12; 
0.2 and 0.5 Gy for 2-time irradiation (day 6 and 9). Solid-type of Lewis 
lung carcinoma was prepared by intramuscularly transplantation of 3 × 
106 cells into the hind limb of C57BL/6 female mice. Tumor volumes 
were measured with calipers and a volume calculated (L+W+W/2). 
The metastases of the lung were counted using a stereoscopic 
microscope. 
Results: Low-dose pulsed X-ray inhibits growth of Lewis lung 
carcinoma cells at all experimental groups. Irradiation with absorbed 
dose 0.12 Gy affects 69 % of tumor inhibition, 0.2 Gy – 56 % and 0.5 Gy 
up to 46 % compare to control group. Inhibition of metastasis growth 
(by square of colonies) was highest in group 0.5 Gy (72 %) and lowest 
at 0.2 Gy absorbed dose (58 %). Applying 0.12 Gy produced 68 % 
decreasing of metastatic colonies square. Same time, index inhibition 
of metastasis (by number of colonies) was highest both in groups 
irradiated with 0.12 and 0.5 Gy (84-85 %) and only 67 % observed in 
group with absorbed dose 0.2 Gy. 
Conclusions: Pulse regime increase antitumor efficacy of low dose X-
ray up to 50 - 70 % and antimetastatic action up to 60 – 80 %. Similar 
effects of non-pulsed X-ray achieved when the absorbed dose exceed 
10 – 20 Gy. 
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Purpose/Objective: To Assess the impact of Personalized Care on 
Treatment Compliance in Cancer Patients  
Materials and Methods: During Jan. 2010 to Jan.2011, 161 patients 
with histologically proven cancer were randomized in two arms: 
study- where patients were provided with personalized care approach, 
patient centred care with requisite related information, whereas 
control arm patients were managed in conventional manner as 
prevalent within the department. All patients were treated as per 
merit of the case and according to departmental policy. Patients were 
evaluated for treatment compliance to the scheduled plan in terms of 
treatment completions and treatment interruptions, dropout rates 
and follow-up rates at the end of 3 months.  
Results: N=161,study- 78, Control- 81; Age: 47.5years (mean), Range-
10-70 yrs; Sex: M:F-1:1.4; Marital status:Married-99%; 
Rural/Urban:Rural-75%; Religion:Hindu-92%; Literacy-39%; 
Occupations: housewives-47%, manual workers-45% (including farmers 
and carpenters), professionals-8%; types of family: joint families-
60%;Referral pattern: within hospital-58%; Sites: Cervix-37%, Head and 
Neck-32%, Breast-8%, GI-7%, brain-4% and others-12%;stage: I=7%, II-
30%, III-21%, IV-31%, stage unknown-11%; Intent of treatment: Radical-
69%,Postoperative-24%, Palliative -7%. Seventy percent of the patients 
completed the prescribed treatment (112/161). The rate of 
completion of treatment in study arm was better than control arm 
(78% vs. 61%) (P=0.02). Of the remaining 49 patients, 16/161 (10%) 
patients were dropped out and 33/161 (20%) patients were not came 
for scheduled treatment. The drop-out rate was similar in both 
control and study arm (10%) while the percent of patients not came 
for treatment was much lower in study arm (12% vs. 29%) (P= 0.011). 
The percentage of patients experiencing treatment interruption in 
those who completed treatment was lower in study arm (12% vs. 15%). 
Study armhad higher number of patients under follow up after 3 
months: 54 (69%) vs.44(53 %).  
Conclusions: The use of personalized care, providing requisite related 
information, communication provision, and supportive care may 
improve treatment compliance in terms of better treatment 
completions, lesser dropouts, low treatment interruptions and better 
follow up.  
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Purpose/Objective: To evaluate and control breakthrough pain (BP) 
episodes in advanced cancer patients (ACP) undergoing radiotherapy 
during proceedings and maneuvers necessary to receive treatment, 
and assess the ability of Fentanyl pectin nasal citrate (FPNC) to 
control these episodes. 
Materials and Methods: Twelve patients with severe BP associated to 
routine radiotherapy procedures and maneuvers were selected to 
receive FPNC for pain relief. Most patients (10/12) suffered from bone 
metastases and showed a low Karnovsky performance status (30-70%). 
BP intensity was evaluated by Visual Analog Scale before and after the 
procedures that triggered it. All patients were already receiving an 
opioid basal treatment at total dose equivalent to 40-80 mg morphine. 
BP was treated before the procedure with a dose of 100-400 µg of 
FPNC. Data related to tolerance, pain relief, onset of the relief and 
efficient dose to allow the procedure were collected. 
Results: In all patients, BP score was reduced at least to 50% after 13 
min (5-30 min) of fentanyl administration. Pain relief started after 7 
min (5-15 min) and the duration of the effect permitted the normal 
procedure development. All patients reported pain control with a dose 
of 200 μg of FPNC except one patient who required progressive doses 
till 600 μg. Five patients reported minor undesirable effects related to 
the FPNC administration. 
Conclusions: Procedures and maneuvers necessary to apply 
radiotherapy treatment in ACP may provoke in some of them severe 
BP episodes, so a simple, rapid and strong analgesic is needed. FPNC 
offers a rapid absorption and pain relief, being particularly efficient 
and well accepted in these patients. This relief allows the completion 
of necessary procedures to administrate treatment without adding 
unnecessary suffering to patients. 
 
 
 
 
 
 
 
 
 
   
